Nationwide COVID-19 Antibody Seroprevalence Estimates by Demographics

2022–2023 survey data provides weighted seroprevalence estimates for SARS-CoV-2 antibodies among U.S. blood donors. The CDC collaborated with Vitalant Research Institute, American Red Cross, and Westat Inc. to collect and analyze de-identified blood samples. Data includes estimates for infection-induced and combined infection- and vaccination-induced antibody prevalence.

Use Cases

• Analyze trends in infection-induced seroprevalence over the Time Period using the Estimate % (weighted) column.
• Compare antibody prevalence across demographic groups using Age, Race, and Sex columns.
• Assess geographic variation in combined infection- and vaccination-induced seroprevalence using Geographic Area and Geographic Identifier.
• Evaluate statistical uncertainty in seroprevalence estimates using the n (Unweighted), 2.5%, and 97.5% columns.

Strengths

• Data includes weighted estimates with confidence intervals (2.5%, 97.5%) for statistical reliability.
• Covers multiple demographic dimensions including Age, Race, Sex, and Geographic Area.
• Provides separate estimates for infection-induced and combined infection- and vaccination-induced seroprevalence via the Indicator column.

Limitations

• Sample size (n) and total row count are unknown, limiting assessment of statistical power.
• Population is limited to blood donors, which may not be fully representative of the general U.S. population.
• Temporal coverage is limited to the 2022–2023 period.

Provenance

Source

data.cdc.gov, from a collaboration between CDC, Vitalant Research Institute, American Red Cross, and Westat Inc.

Collection Method

De-identified blood samples from donors were tested for SARS-CoV-2 anti-spike and anti-nucleocapsid antibodies.

Time Range

2022–2023

Freshness

Last updated on 2025-02-23.

Geography

United States, with breakdowns by Geographic Area.